Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

Molecular Pharmacology

Volumn 75, Issue 1, 2009, Pages 196-207

  Marek, Lindsay ^a   Ware, Kathryn E ^a   Fritzsche, Alexa ^a   Hercule, Paula ^a   Helton, Wallace R ^b   Smith, Jennifer E ^a   McDermott, Lee A ^c   Coldren, Christopher D ^a,b   Nemenoff, Raphael A ^a,b   Merrick, Daniel T ^b   Helfrich, Barbara A ^a,b   Bunn Jr , Paul A ^b   Heasley, Lynn E ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (ANTI 3 HYDROXYCYCLOPENTYL) 3 (4 METHOXYPHENYL) 7 PHENYLAMINO 3,4 DIHYDRO 1H PYRIMIDO[4,5 D]PYRIMIDIN 2 ONE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2B; FIBROBLAST GROWTH FACTOR RECEPTOR 2C; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR BLOCKING AGENT; RO 4383596; UNCLASSIFIED DRUG; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FIBROBLAST GROWTH FACTORS; HUMANS; LUNG NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 58849122812     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.049544     Document Type: Article

References (37)

1. Berger W, Setinek U, Mohr T, Kindas-Mügge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, and Micksche M (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83:415-423.
2. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, and Minna JD (1988) Chemosensitivity testing of human lung cancer cell lines using the MTT assay. British Journal of Cancer 57:540-547.
3. Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A, and Pierce GF (1999) Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer 81:451-458.
4. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, et al. (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4:521-528.
5. Dancey JE (2004) Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 5:411-415.
6. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595.
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
8. Eswarakumar VP, Lax I, and Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
9. Grose R and Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179 -186.
10. Hafizi S and Dahlbäck B (2006) Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 273:5231-5244.
11. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501.
12. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
13. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, et al. (2006) Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12:7117-7125.
14. Hirsch FR and Bunn PA Jr (2005) Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol 23:9044 -9047.
15. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C, and Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798 -3807.
16. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, and Weinberg RA (2007) Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes. Cancer Cell 12:160 -170.
17. Kranenburg AR, De Boer WI, Van Krieken JH, Mooi WJ, Walters JE, Saxena PR, Sterk PJ, and Sharma HS (2002) Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 27:517-525.
18. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WI, and Sharma HS (2005) Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1. J Pathol 206:28-38.
19. Kuhn H, Köpff C, Konrad J, Riedel A, Gessner C, and Wirtz H (2004) Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 44:167-174.
20. Kwabi-Addo B, Ropiquet F, Giri D, and Ittmann M (2001) Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46:163-172.
21. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, and Pan BS (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67:2081-2088.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
23. McDermott LA, Simcox M, Higgins B, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, et al. (2005) RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. Bioorg Med Chem 13:4835-4841.
24. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, et al. (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109.
25. Mohammadi M, Olsen SK, and Ibrahimi OA (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16:107-137.
26. Morgillo F and Lee HY (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8:298-310.
27. Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, and Podolsky DK (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 54:5206 -5211.
28. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, and Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356 -361.
29. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, and Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
30. Powell PP, Wang CC, Horinouchi H, Shepherd K, Jacobson M, Lipson M, and Jones R (1998) Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung. Am J Respir Cell Mol Biol 19:563-572.
31. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203.
32. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, and Dmitrovsky E (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522.
33. Schwartz AG and Ruckdeschel JC (2006) Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:16 -22.
34. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, and Wu CW (2005) Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7:1058-1064.
35. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290.
36. Wimmel A, Glitz D, Kraus A, Roeder J, and Schuermann M (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37:2264 -2274.
37. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65:5561-5570.